Free Trial

Windtree Therapeutics (WINT) Stock Price, News & Analysis

-0.13 (-2.97%)
(As of 05/21/2024 ET)
Today's Range
50-Day Range
52-Week Range
7,349 shs
Average Volume
24,041 shs
Market Capitalization
$2.51 million
P/E Ratio
Dividend Yield
Price Target
WINT stock logo

About Windtree Therapeutics Stock (NASDAQ:WINT)

Windtree Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of acute cardiovascular diseases. The company's lead product is istaroxime which is in Phase 2b clinical trial for the treatment of acute decompensated heart failure, as well as for the treatment of early cardiogenic shock. It also develops AEROSURF, an aerosolized KL4 surfactant, which is in Phase 2b clinical trial to treat respiratory distress syndrome in premature infants; Surfaxin, a lyophilized KL4 surfactant, which is in Phase 2a clinical trial for the treatment of lung injury resulting from COVID-19; Rostafuroxin that is in Phase 2b clinical trial for the treatment of genetically associated hypertension; and oral and intravenous SERCA2a activator, which is in preclinical trial for the treatment of chronic and acute heart failure. In addition, it is developing aPKCi Inhibitorfor the treatment of cutaneous malignancies and solid tumors that is in preclinical trials. Windtree Therapeutics, Inc. has collaboration with Chang Gung University; collaboration with Universita degli Studi di Milano-Bicocca for the discovery and development of new SERCA2a compounds for the treatment of chronic and acute human heart failure; a strategic alliance with Laboratorios del Dr. Esteve, S.A. for the development, marketing, and sales of a portfolio of potential KL4 surfactant products; license, development and commercialization agreement with Lee's Pharmaceutical (HK) Ltd. and Zhaoke Pharmaceutical (Hefei) Co. Ltd.; license agreement with Philip Morris USA, Inc. and Johnson & Johnson; and collaboration with Battelle Memorial Institute for development of its ADS for use in its phase III program. The company was formerly known as Discovery Laboratories, Inc. and changed its name to Windtree Therapeutics, Inc. in April 2016. The company was founded in 1992 and is headquartered in Warrington, Pennsylvania.

WINT Stock Price History

WINT Stock News Headlines

Windtree Therapeutics Inc WINT
Windtree Therapeutics is dangerously low on cash
Windtree Therapeutics Announces Reverse Stock Split
Windtree Therapeutics Inc
See More Headlines
Receive WINT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Windtree Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Fiscal Year End

Industry, Sector and Symbol

Biological products, except diagnostic
Current Symbol
Year Founded


Net Income
Pretax Margin


Sales & Book Value

Annual Sales
Book Value
$10.17 per share


Free Float
Market Cap
$2.51 million
Not Optionable
13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Key Executives

  • Mr. Craig E. FraserMr. Craig E. Fraser (Age 59)
    Chairman, President, CEO & Interim Principal Officer
    Comp: $567.2k
  • Mr. Eric L. Curtis M.B.A. (Age 56)
    Senior VP & COO
    Comp: $411.3k
  • Dr. Steven G. Simonson M.D. (Age 65)
    M.H.S, Senior VP & Chief Medical Officer
    Comp: $448k
  • Ms. Jamie McAndrew (Age 43)
    VP, Controller, Chief Accounting Officer & Corporate Secretary
  • Mr. George Cox (Age 72)
    Vice President of Technical Operations
  • Dr. Pratap Paruchuru
    Executive Director of Clinical Development
  • Ms. Tracy Rarick
    Head of Operations & Program Management

WINT Stock Analysis - Frequently Asked Questions

Should I buy or sell Windtree Therapeutics stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Windtree Therapeutics in the last twelve months. There are currently 1 hold rating for the stock. The consensus among Wall Street analysts is that investors should "hold" WINT shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in WINT, but not buy additional shares or sell existing shares.
View WINT analyst ratings
or view top-rated stocks.

How have WINT shares performed in 2024?

Windtree Therapeutics' stock was trading at $12.9420 at the beginning of the year. Since then, WINT stock has decreased by 67.2% and is now trading at $4.24.
View the best growth stocks for 2024 here

How were Windtree Therapeutics' earnings last quarter?

Windtree Therapeutics, Inc. (NASDAQ:WINT) issued its earnings results on Tuesday, April, 16th. The company reported ($13.31) earnings per share for the quarter.

When did Windtree Therapeutics' stock split?

Windtree Therapeutics shares reverse split on the morning of Monday, April 22nd 2024. The 1-18 reverse split was announced on Monday, April 22nd 2024. The number of shares owned by shareholders was adjusted after the closing bell on Monday, April 22nd 2024. An investor that had 100 shares of stock prior to the reverse split would have 6 shares after the split.

How do I buy shares of Windtree Therapeutics?

Shares of WINT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:WINT) was last updated on 5/21/2024 by Staff

From Our Partners